Used in targeted cancer therapy, particularly in inhibiting tumor angiogenesis and blocking the interaction between VEGF165 and neuropilin-1 (NRP1). This antibody disrupts signaling pathways that promote blood vessel formation in tumors, thereby suppressing tumor growth and metastasis. It is being investigated for use in solid tumors, including breast, lung, and pancreatic cancers, often in combination with other anti-angiogenic or chemotherapeutic agents. Its high specificity enhances therapeutic efficacy while minimizing off-target effects, making it a promising candidate in oncology biologics development.